



Republic of the Philippines
 Department of Health
OFFICE OF THE SECRETARY

MEDICINES RECOMMENDED FOR INCLUSION AND NON-INCLUSION IN THE PHILIPPINE NATIONAL FORMULARY (PNF)

On 26 July 2022, the Health Technology Assessment Council (HTAC) announced its preliminary recommendation for the government financing of *insulin glargine* and *insulin detemir* through its inclusion in the PNF (as of 25 July 2022), which was posted for appeals until 11 August 2022.

After consideration of the missed information in the preliminary recommendation that insulin detemir is still patented until July 2028 and its possible implications on its economic impact, the HTAC would like to announce that it has made the following revisions to its recommendation as shown in the table below.

	Preliminary HTAC Recommendation	Revised HTAC Recommendation
Insulin glargine 100 IU/mL vial and pen	<p>“Overall, the HTAC recommends the government financing of insulin glargine and insulin detemir through its inclusion in the PNF. Both drugs have shown comparable efficacy and acceptable safety profiles in both type 1 and type 2 diabetes mellitus patients as compared to NPH insulin. Furthermore, both interventions have shown lower risks of severe hypoglycemia.</p> <p>The costing analysis of locally available insulin brands have shown that insulin glargine and detemir incurs a higher individual cost and budget impact to the government as compared to NPH insulin. However, cost-effectiveness studies included in the WHO review have shown that the administration of these drugs are cost-effective as compared to NPH insulin”</p>	<p>The HTAC <u>recommends the government financing of both insulin glargine 10mL vial (100 IU/ml) and 3mL pre-filled pen (100 IU/ml) through its inclusion in the PNF.</u> Insulin glargine has shown comparable efficacy and acceptable safety profiles in both type 1 and type 2 diabetes mellitus patients as compared to NPH insulin. Furthermore, the intervention has shown lower risks of severe hypoglycemia.</p> <p><u>Although the cost-effectiveness of insulin glargine pen and vial cannot be ascertained in the Philippine setting based on the WHO review and its high budget impact, the availability of numerous biosimilars in the market will enable the lowering of cost of the drug through competitive bidding.</u></p>
Insulin detemir 100 IU/mL pen		<p>The HTAC <u>does not recommend the government financing and inclusion of insulin detemir pen (100IU/mL, 3mL prefilled pen) in the PNF.</u> Insulin detemir has shown comparable</p>

		<p>efficacy and acceptable safety profiles in both type 1 and type 2 diabetes mellitus patients as compared to NPH insulin and lower risks of severe hypoglycemia, <u>however, insulin detemir pen incurs a high budget impact</u> Additionally, <u>since there is no biosimilar competitor, it is less likely to have a low bidding price.</u></p>
--	--	---

With the change in its recommendation, the HTAC would like to reopen the appeals period. All comments, inputs, and/or appeals may be submitted until **07 September 2022**, for the consideration of the HTAC, through email at hta@doh.gov.ph.

For more information on the evidence and references considered by HTAC, you may access the evidence summary through this link: https://bit.ly/HTACrevisedPR_InsulinDetemirandGlargine

Please use the prescribed form for appeals which is accessible through this link: hta.doh.gov.ph/topic-nomination/. Appeals not following the prescribed format, and those submitted beyond the deadline shall not be entertained.

Should you wish to submit hard copies, you may drop them off at the following address:
4th floor, Philippine Blood Disease, and Transfusion Center, Lung Center Compound, Quezon Avenue, Quezon City.

ANNA MELISSA S. GUERRERO, MD, MPH (HTA)
Director IV, Health Technology Assessment Division
Health Regulation Team